Lisata Therapeutics Terminates Merger Agreement With Kuva Labs; Termination Due To Kuva Labs' Failure To Obtain Financing, Accept Tendered Shares; Board To Carry Out Strategic Options Including Asset Sale
https://www.sec.gov/ix?doc=/Archives/edgar/data/320017/000114036126029541/ef20078724_8k.htm
Share
Why It Matters
A company called Lisata ended a plan to merge with another company because that company couldn't get the money it promised. Now Lisata's leaders will look at other choices, like selling its stuff.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.